Patents by Inventor Devis Galesso
Devis Galesso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11357858Abstract: Disclosed are pharmaceutical compositions in gel form comprising a hydrophilic matrix consisting of a hyaluronic acid derivative containing an amide local anaesthetic in base form.Type: GrantFiled: January 23, 2019Date of Patent: June 14, 2022Assignee: FIDIA FARMACEUTICI S.p.A.Inventors: Andrea Pastorello, Fabio Bettella, Devis Galesso
-
Patent number: 10898510Abstract: Disclosed is grade 2 sulphated hyaluronic acid having 2 to 60% molar, preferably 15 to 35%, and even more preferably between 20 and 25%, of the carboxyl groups functionalized with dopamine conjugated directly via an amide bond or by means of a spacer having an amino group for the formation of an amide bond with the carboxyl groups of hyaluronic acid and of a carboxyl group for the formation of an amide bond with the amino group of dopamine.Type: GrantFiled: November 13, 2017Date of Patent: January 26, 2021Assignee: FIDIA FARMACEUTICI S. P. A.Inventors: Cristian Guarise, Stefano Pluda, Devis Galesso
-
Publication number: 20200360519Abstract: Disclosed are pharmaceutical compositions in gel form comprising a hydrophilic matrix consisting of a hyaluronic acid derivative containing an amide local anaesthetic in base form.Type: ApplicationFiled: January 23, 2019Publication date: November 19, 2020Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Andrea PASTORELLO, Fabio BETTELLA, Devis GALESSO
-
Patent number: 10548918Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and antiinflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and antiinflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.Type: GrantFiled: September 20, 2017Date of Patent: February 4, 2020Assignee: FIDIA FARMACEUTICI S.p.A.Inventors: Devis Galesso, Anna Maria Zanellato
-
Publication number: 20190321390Abstract: Disclosed is grade 2 sulphated hyaluronic acid having 2 to 60% molar, preferably 15 to 35%, and even more preferably between 20 and 25%, of the carboxyl groups functionalized with dopamine conjugated directly via an amide bond or by means of a spacer having an amino group for the formation of an amide bond with the carboxyl groups of hyaluronic acid and of a carboxyl group for the formation of an amide bond with the amino group of dopamine.Type: ApplicationFiled: November 13, 2017Publication date: October 24, 2019Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Cristian GUARISE, Stefano PLUDA, Devis GALESSO
-
Publication number: 20180008628Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and antiinflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and antiinflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.Type: ApplicationFiled: September 20, 2017Publication date: January 11, 2018Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Devis GALESSO, Anna Maria ZANELLATO
-
Patent number: 9808482Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.Type: GrantFiled: May 11, 2010Date of Patent: November 7, 2017Assignee: FIDIA FARMACEUTICI S.p.A.Inventors: Devis Galesso, Anna Maria Zanellato
-
Patent number: 8992890Abstract: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.Type: GrantFiled: February 13, 2012Date of Patent: March 31, 2015Assignee: Fidia Farmaceutici S.p.A.Inventors: Andrea Pastorello, Devis Galesso, Fabio Bettella
-
Publication number: 20130323183Abstract: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.Type: ApplicationFiled: February 13, 2012Publication date: December 5, 2013Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Andrea Pastorello, Devis Galesso, Fabio Bettella
-
Patent number: 8512752Abstract: Crosslinked derivatives of polycarboxylated polysaccharides are described, wherein at least one of the polysaccharide chains consists of hyaluronic acid or a derivative thereof, crosslinked by means of reactions of the “click chemistry” type and their use in the field of viscosupplementation, plastic surgery, oncologic and reconstructive surgery and also as matrices for controlled release systems of biologically and/or pharmacologically active molecules and/or macromolecules.Type: GrantFiled: September 5, 2007Date of Patent: August 20, 2013Assignee: Fidia Farmaceutici S.p.A.Inventors: Di Meo Chiara, Devis Galesso, Ada Mascolo, Fabiana Crescenzi, Alberta Crescenzi, Flavia Crescenzi, Fulvia Crescenzi, Laura Crescenzi, Vittoria Crescenzi
-
Patent number: 8263118Abstract: The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.Type: GrantFiled: February 15, 2012Date of Patent: September 11, 2012Assignee: Fidia Farmaceutici S.p.A.Inventors: Lanfranco Callegaro, Devis Galesso, Anna Taglienti
-
Publication number: 20120148667Abstract: The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.Type: ApplicationFiled: February 15, 2012Publication date: June 14, 2012Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Lanfranco CALLEGARO, Devis GALESSO, Anna TAGLIENTI
-
Publication number: 20120101059Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.Type: ApplicationFiled: May 11, 2010Publication date: April 26, 2012Applicant: Fidia Farmaceutici S.p.A.Inventors: Devis Galesso, Anna Maria Zanellato
-
Publication number: 20100291171Abstract: Crosslinked derivatives of polycarboxylated polysaccharides are described, wherein at least one of the polysaccharide chains consists of hyaluronic acid or a derivative thereof, crosslinked by means of reactions of the “click chemistry” type and their use in the field of viscosupplementation, plastic surgery, oncologic and reconstructive surgery and also as matrices for controlled release systems of biologically and/or pharmacologically active molecules and/or macromolecules.Type: ApplicationFiled: September 5, 2007Publication date: November 18, 2010Applicant: Fidia Farmaceutici S.p.A.Inventors: Vittorio Crescenzi, Di Meo Chiara, Devis Galesso, Ada Mascolo
-
Publication number: 20080145415Abstract: The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.Type: ApplicationFiled: April 21, 2006Publication date: June 19, 2008Inventors: Lanfranco Callegaro, Devis Galesso, Anna Taglienti